Cullinan Therapeutics (CGEM) Earnings Date & Reports

Key Takeaways

• Cullinan Therapeutics (NASDAQ: CGEM) is expected to report third-quarter 2026 results in early November, before the market opens.
• Wall Street consensus calls for a net loss of roughly $0.84 per share, versus a $0.77 loss in the same quarter a year earlier.
• As a clinical-stage biopharmaceutical company, Cullinan generates minimal revenue; consensus revenue sits near $2 million.
• Investor attention will center on pipeline updates for velinotamig and zipalertinib rather than on bottom-line figures.
• Cullinan has beaten earnings-per-share (EPS) consensus in six of its last eight quarters, though revenue has consistently been near zero.

Earnings Context and Why It Matters

For a pre-revenue drug developer like Cullinan Therapeutics, quarterly earnings serve less as a profit report and more as a window into clinical execution, spending discipline, and cash runway. The company is advancing therapies for autoimmune diseases and cancer, including its lead BCMAxCD3 (B-cell maturation antigen and CD3) bispecific T-cell engager, velinotamig, and zipalertinib, a lung-cancer candidate developed with Taiho Pharmaceutical. With no approved products yet generating sales, the headline numbers are driven almost entirely by research and development costs. Investors and analysts will look past the reported loss to gauge whether the company remains on track toward key data readouts and potential regulatory milestones.

Earnings Expectations

Analysts expect Cullinan Therapeutics to report a third-quarter 2026 loss of approximately $0.84 per share, based on a consensus of nine analysts, with individual estimates ranging from a loss of $1.04 to a loss of $0.71. That compares with a reported loss of $0.77 per share in the third quarter of 2025. Consensus revenue is modest, near $2 million, reflecting the company's clinical-stage status and a lack of product sales.

In its most recent report for the second quarter of 2026, Cullinan posted a loss of $0.81 per share, essentially in line with the $0.80 consensus estimate. The company has exceeded EPS expectations in six of its past eight quarters, though the small magnitude of these beats reflects the relatively predictable nature of its operating-expense base rather than a swing in commercial performance. With cash and investments reported at approximately $334.5 million as of mid-2026, investors will also be watching the rate of cash burn and any commentary on how long existing funds are expected to last.

AI Screener

For traders and investors looking to cut through thousands of potential opportunities, Tickeron's AI Screener offers an AI-powered stock and ETF discovery tool that filters the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is designed to help identify trade ideas, trending stocks, breakout candidates, and emerging market opportunities far more efficiently than manual screening. Explore the AI Screener to see how it can support your own research process.

Market Reaction and Investor Sentiment

Sentiment heading into Cullinan's third-quarter report is cautiously optimistic, with analysts maintaining a consensus "Moderate Buy" rating and an average price target well above recent trading levels. However, the range of views remains wide, with price targets spanning from the low $20s to the mid-$40s, underscoring the binary, data-driven nature of biotech investing. Because the reported loss is largely anticipated, the stock's near-term reaction will likely hinge less on the EPS figure itself and more on any clinical updates, enrollment progress, or changes to development timelines disclosed alongside results. Key risk factors include potential trial delays, higher-than-expected spending, and any negative safety signals that could emerge from ongoing studies.

Forward Outlook and Key Factors to Monitor

Looking beyond the third-quarter print, investors should focus on the company's clinical catalysts rather than quarterly income-statement movements. The most closely watched program is velinotamig, an investigational bispecific T-cell engager being developed for autoimmune conditions. Under its 2025 agreement with Genrix Biopharmaceutical, Cullinan holds global rights outside Greater China and has committed to substantial development, regulatory, and sales-based milestone payments. Progress updates and any new efficacy or safety data will be pivotal.

A second area to monitor is zipalertinib, a targeted therapy for a genetically defined subset of non-small cell lung cancer (NSCLC, a common form of lung cancer) that Cullinan is co-developing with Taiho Pharmaceutical. In late 2025, Taiho initiated an independent global Phase 3 trial in an additional indication, and Cullinan remains eligible for up to $130 million in U.S. regulatory milestones tied to this program.

Finally, watch the company's cash position and spending trajectory. With no product revenue, Cullinan relies on its balance sheet to fund multiple clinical programs. How management frames its cash runway, and whether it signals any future financing or partnership activity, will be important signals for shareholders assessing the path toward data readouts and potential commercialization.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations